CN101969941B - 用作为药物的氨基酸衍生物 - Google Patents

用作为药物的氨基酸衍生物 Download PDF

Info

Publication number
CN101969941B
CN101969941B CN200980103402.1A CN200980103402A CN101969941B CN 101969941 B CN101969941 B CN 101969941B CN 200980103402 A CN200980103402 A CN 200980103402A CN 101969941 B CN101969941 B CN 101969941B
Authority
CN
China
Prior art keywords
medicine
prodrug
guanidine
amidine
pentamidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980103402.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN101969941A (zh
Inventor
B·克莱蒙特
C·里赫
H·胡恩格林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dritte Patentportfolio Beteiligungs GmbH and Co KG
Original Assignee
Dritte Patentportfolio Beteiligungs GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dritte Patentportfolio Beteiligungs GmbH and Co KG filed Critical Dritte Patentportfolio Beteiligungs GmbH and Co KG
Publication of CN101969941A publication Critical patent/CN101969941A/zh
Application granted granted Critical
Publication of CN101969941B publication Critical patent/CN101969941B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/62—Oximes having oxygen atoms of oxyimino groups esterified
    • C07C251/64—Oximes having oxygen atoms of oxyimino groups esterified by carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C249/00—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C249/04—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes
    • C07C249/12—Preparation of compounds containing nitrogen atoms doubly-bound to a carbon skeleton of oximes by reactions not involving the formation of oxyimino groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200980103402.1A 2008-02-01 2009-02-02 用作为药物的氨基酸衍生物 Expired - Fee Related CN101969941B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102008007440A DE102008007440A1 (de) 2008-02-01 2008-02-01 Aminosäurederivate als Arzneistoffe
DE102008007440.3 2008-02-01
PCT/EP2009/051162 WO2009095503A2 (de) 2008-02-01 2009-02-02 Aminosaeurederivate als arzneistoffe

Publications (2)

Publication Number Publication Date
CN101969941A CN101969941A (zh) 2011-02-09
CN101969941B true CN101969941B (zh) 2014-11-26

Family

ID=40672206

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980103402.1A Expired - Fee Related CN101969941B (zh) 2008-02-01 2009-02-02 用作为药物的氨基酸衍生物

Country Status (13)

Country Link
US (2) US8658826B2 (ko)
EP (2) EP2848249A3 (ko)
JP (1) JP5631218B2 (ko)
KR (2) KR20160080116A (ko)
CN (1) CN101969941B (ko)
AU (1) AU2009209564B2 (ko)
BR (1) BRPI0906733A2 (ko)
CA (1) CA2713780C (ko)
DE (1) DE102008007440A1 (ko)
HK (1) HK1209022A1 (ko)
IL (1) IL207287A0 (ko)
WO (1) WO2009095503A2 (ko)
ZA (1) ZA201004864B (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102009004204A1 (de) * 2009-01-09 2010-07-15 Christian-Albrechts-Universität Zu Kiel Verfahren zur verbesserten Bioaktivierung von Arzneistoffen
JP5429488B2 (ja) * 2010-03-31 2014-02-26 セイコーエプソン株式会社 液体噴射装置
DK2550966T3 (en) * 2011-07-25 2017-02-06 Dritte Patentportfolio Beteili Dabigatran amidoxic acid esters as prodrugs and their use as a drug

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1266427A (zh) * 1997-06-19 2000-09-13 阿斯特拉公司 新的脒基衍生物及其作为凝血酶抑制剂的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4321444A1 (de) * 1993-06-28 1995-01-05 Bernd Prof Dr Clement Pharmazeutische Zubereitung
WO2001097794A2 (en) * 2000-06-21 2001-12-27 Georgetown University Inhibitors of matriptase for the treatment of cancer
DE10323898A1 (de) * 2003-05-26 2004-12-23 Wilex Ag Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe
EP1767526B1 (en) * 2004-06-30 2012-10-24 Toyama Chemical Co., Ltd. Arylamidine derivative, salt thereof and antifungal containing these
WO2006011499A1 (ja) * 2004-07-28 2006-02-02 Toyama Chemical Co., Ltd. 新規なアリールアミジン誘導体およびその塩ならびにそれらを含有する抗真菌剤
DE102006034256A1 (de) * 2006-07-21 2008-01-31 Christian-Albrechts-Universität Zu Kiel Verbesserung der Bioverfügbarkeit von Wirkstoffen mit Amidinfunktion in Arzneimitteln

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1266427A (zh) * 1997-06-19 2000-09-13 阿斯特拉公司 新的脒基衍生物及其作为凝血酶抑制剂的用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Identification of GS 4104 as an Orally Bioavailable Prodrug of the Influenza Virus Neuraminidase Inhibitor GS 4071;WEIXING LI, et al.;《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》;19980331;第42卷(第3期);647-653 *
WEIXING LI, et al..Identification of GS 4104 as an Orally Bioavailable Prodrug of the Influenza Virus Neuraminidase Inhibitor GS 4071.《ANTIMICROBIAL AGENTS AND CHEMOTHERAPY》.1998,第42卷(第3期),647-653. *

Also Published As

Publication number Publication date
CA2713780A1 (en) 2009-08-06
US20110021835A1 (en) 2011-01-27
WO2009095503A3 (de) 2009-12-03
JP5631218B2 (ja) 2014-11-26
US8658826B2 (en) 2014-02-25
AU2009209564A1 (en) 2009-08-06
IL207287A0 (en) 2010-12-30
WO2009095503A2 (de) 2009-08-06
DE102008007440A1 (de) 2009-08-13
EP2242488A2 (de) 2010-10-27
KR20100106588A (ko) 2010-10-01
EP2848249A3 (de) 2015-07-22
JP2012516830A (ja) 2012-07-26
EP2848249A2 (de) 2015-03-18
HK1209022A1 (en) 2016-03-24
KR20160080116A (ko) 2016-07-07
CN101969941A (zh) 2011-02-09
US20140066648A1 (en) 2014-03-06
BRPI0906733A2 (pt) 2015-07-14
AU2009209564B2 (en) 2015-07-02
CA2713780C (en) 2016-09-20
ZA201004864B (en) 2011-03-30

Similar Documents

Publication Publication Date Title
CN101951897B (zh) 偕胺肟羧酸酯和n-羟胍羧酸酯用于制备前药的用途
EP2061749B1 (en) Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate
DK2046732T5 (en) Improving the bioavailability of active substances with amidine function in drugs.
CN101969941B (zh) 用作为药物的氨基酸衍生物
CN102548988A (zh) 阿齐沙坦有机胺盐及其制备方法和用途
CN101580530A (zh) 五环三萜类化合物的氨基酸偶合物前药及其医药用途
EP2376074B1 (de) Verfahren zur verbesserten bioaktivierung von arzneistoffen
JP5061352B2 (ja) 肝臓疾患治療剤及び肝機能改善剤
AU2014200451B2 (en) Use of amidoxime carboxylic acid esters and n-hydroxyguanidine carboxylic acid esters for producing prodrugs
KR20160027967A (ko) 전구약물을 생성하기 위한 아미드옥심 카르복실산 에스테르류 및 엔-하이드록시구아니딘 카르복실산 에스테르류의 용도

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20141126

Termination date: 20170202